|
| |
Joint Symposium with CLINIGENE
|
| 8.30 – 10.30 a.m. |
Gene Therapy:
Perspectives and Clinical Implications
Chair: B. Gansbacher, D. Klatzmann |
8.30 – 8.55 a.m.
8.55 – 9.20 a.m.
9.20 – 9.45 a.m.
9.45 – 10.10 a.m.
10.10 – 10.35 a.m.
10.35 – 10.45 a.m. |
Gene therapy/immunotherapy of glioblastoma
N. Kasahara, Los Angeles
Manipulating regulatory T cells for cancer therapy
D. Klatzmann, Paris
Oncolytic adenoviruses for treatment of resistant tumours
P. Holm, Munich
Antisense strategies in prostate cancer
I. Eder, Innsbruck
Pdcd4, a colon cancer prognostic regulated by a micro-RNA
H. Allgayer, Mannheim
Free communication
Allogeneic gene-modifi ed tumor cell vaccine (RCC-26/CD80/IL-2)
in patients with metastatic renal cell carcinoma – a phase
I trial
A. Buchner, Munich
|
| 10.45 – 11.30 a.m. |
Coffee Break |
11.30 – 12.55 a.m.
|
Monoclonal Antibodies
Chair: L. Bergmann, G. Riethmüller |
11.30 – 11.55 a.m.
11.55– 12.20 a.m.
12.20 – 12.45 a.m.
12.45 – 12.55 a.m.
|
Things we have learned about the CTLA4 antibodies
J. Gomez-Navarro, New London
A novel 3rd generation CD20 antibody with increased direct cell
death induction and ADCC
Paolo Umaña, Schlieren
CD23 monoclonal antibody, lumiliximab, for patients with
chronic lymphocytic leukemia (CLL)
N. Pathan, San Diego
Free communication
The bispecifi c antibody MT110 targeting EpCAM/CD3 induces
specifi c redirected lysis of pleural carcinoma cells of metastatic
breast cancer patients
B. Mayer, Munich |
| 12.55 – 2.00 p.m. |
Lunch |
2.00 – 4.05 p.m.
|
Monoclonal Antibodies
Chair: M.M. Heiss, C. Peschel |
2.00 – 2.25 p.m.
2.25 - 2.50 p.m.
2.50 – 3.15 p.m.
3.15 – 3.40 p.m.
3.40 – 4.05 p.m.
|
Preclinical and early clinical development of cetuximab
O. Kisker, Darmstadt
Role of cetuximab in head and neck cancer
G. Sprinzl, Innsbruck
Resistance mechanisms against EGF blockers
Y. Yarden, Rehovot
EGFR-Inhibition in relation to RAS-mutational status and
microsatellite instability in colorectal cancer
L. Puig, Paris
Intraperitoneal treatment of malignant ascites using the
three-functional antibody catumaxomab – results of a phase
2/3 study
M.M. Heiss, Munich |
| 4.05 - 4.40 p.m. |
Coffee Break |
4.40 - 5.45 p.m.
|
Signal Transduction
Chair: M. Scheulen, Y. Takaue |
4.40 – 4.55 p.m.
4.55 – 5.20 p.m.
5.20 – 5.45 p.m.
8.00 p.m. |
Preclinical and clinical development of histone-deacety laseinhibitors
T. Beckers, Freiburg
Imatinib resistance in GIST
H.-U. Schildhaus, Bonn
Preclinical and clinical dvelopment of HSP-90-Inhibitors
S.Y. Sharp, Surrey, UK
Speakers Dinner |